



Drug Name: Daliresp (roflumilast)

Reviewed: 11/2019, 4/2020, 5/2021, 4/2022

Required Medical Information:	The member has trialed and experienced an inadequate treatment response or intolerance to an inhaled corticosteroid (ICS)/long-acting beta agonist (LABA) combination therapy or a long-acting muscarinic antagonist (LAMA) /LABA combination therapy or an ICS/LAMA/LABA combination therapy
Coverage Duration:	12 months
Coding Logic for Step Therapy:	Daliresp will pay if there is at least one paid claim within the last 90 days of formulary Advair HFA, Breo Ellipta, Dulera, fluticasone-salmeterol, Symbicort, Wixela Inhub, Anoro Ellipta, Stiolto Respimat, Trelegy Ellipta, or Daliresp